TLTFF (Theralase Technologies) Current Accrued Expense: $0.35 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TLTFF Theralase Technologies Inc TLTFF
37 GF Score
Price $0.20
GF Value $0.13
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Theralase Technologies Current Accrued Expense?

Theralase Technologies TLTFF +6.67% 37 Current Accrued Expense is $0.35 Mil as of Mar. 2026. GuruFocus rates TLTFF with a GF Score™ of 37/100 and a GF Value™ of $0.13 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Theralase Technologies's Current Accrued Expense for the quarter that ended in Mar. 2026 was $0.35 Mil.

Theralase Technologies's quarterly Current Accrued Expense declined from Sep. 2025 ($0.41 Mil) to Dec. 2025 ($0.34 Mil) but then increased from Dec. 2025 ($0.34 Mil) to Mar. 2026 ($0.35 Mil).

Theralase Technologies's annual Current Accrued Expense increased from Dec. 2023 ($0.21 Mil) to Dec. 2024 ($0.37 Mil) but then declined from Dec. 2024 ($0.37 Mil) to Dec. 2025 ($0.34 Mil).

Theralase Technologies Current Accrued Expense Related Terms

Theralase Technologies Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Theralase Technologies's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theralase Technologies Current Accrued Expense Chart

Theralase Technologies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.27 0.19 0.21 0.37 0.34

Theralase Technologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.34 0.31 0.41 0.34 0.35
TLTFF
37GF Score
Theralase Technologies Inc TLTFF
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Theralase Technologies Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.35 Mil mean?
Theralase Technologies (TLTFF) has a Current Accrued Expense of $0.35 Mil as of Mar. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Theralase Technologies and its competitors.
Is Theralase Technologies' Current Accrued Expense too high?
Theralase Technologies' current Current Accrued Expense is $0.35 Mil. Overall, Theralase Technologies has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Theralase Technologies' Current Accrued Expense compare to ABT and SYK?
Theralase Technologies' Current Accrued Expense of $0.35 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Medical Devices & Instruments company?
A good Current Accrued Expense depends on the Medical Devices & Instruments industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Theralase Technologies and its competitors. Theralase Technologies's current Current Accrued Expense is $0.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theralase Technologies stock overvalued right now?
Based on GuruFocus' analysis, Theralase Technologies (TLTFF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.20 — trading 57.5% above its estimated fair value. The current Current Accrued Expense is $0.35 Mil. Theralase Technologies' overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Theralase Technologies (TLTFF), the current Current Accrued Expense is $0.35 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Theralase Technologies (TLTFF) Overvalued in 2026?

Based on GuruFocus' analysis, Theralase Technologies stock appears to be overvalued. The current stock price of $0.20 is trading 57.5% above its estimated GF Value™ of $0.13. GuruFocus considers Theralase Technologies to be Significantly Overvalued.

Key valuation signals for TLTFF:

  • Current Accrued Expense: $0.35 Mil
  • GF Value™: $0.13 vs. price of $0.20 (57.5% above fair value)
  • GF Score™: 37/100 with 4 warning signs

No single metric tells the full story. See the TLTFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Theralase Technologies Business Description

Other Exchanges TTX:GermanyTLT:Canada
Address 41 Hollinger Road, Toronto, ON, CAN, M4B 3G4
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
37GF Score

Get the complete analysis for TLTFF

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.20
Price
$0.13
GF Value